NCT07458087 is a NA clinical trial of ACCURO 3S in Neuraxial Technique, sponsored by Yale University.

Who is sponsoring NCT07458087?

NCT07458087 is sponsored by Yale University.

What drugs are being tested in NCT07458087?

Interventions in NCT07458087: ACCURO 3S.

What condition does NCT07458087 study?

NCT07458087 studies Neuraxial Technique.

Is NCT07458087 still recruiting?

NCT07458087 is currently not yet recruiting. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT07458087

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Accuracy of the Accuro 3S

Not yet recruiting NA Last updated 9 March 2026

What this trial tests

NA trial testing ACCURO 3S in Neuraxial Technique in 50 participants. Not yet recruiting.

Timeline

15 July 2026

Primary endpoint
15 January 2028

15 January 2028

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	50
Start date	15 July 2026
Primary completion	15 January 2028
Estimated completion	15 January 2028
Sites	1 location across United States

Drugs / interventions tested

ACCURO 3S

Conditions studied

Neuraxial Technique — all drugs for Neuraxial Technique →

Sponsor

Yale University

Who can join

Adults 18 to 85, any sex, with Neuraxial Technique. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to evaluate the feasibility and accuracy of the Accuro 3S to provide live guidance when performing a neuraxial technique (e.g., spinal, or epidural). The Accuro 3S is a new device that was designed to allow for midline live neuraxial guidance. If the device can perform as the manufacturers claim the device will permit the performance of epidurals as close as doing them under fluoroscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
NCT07362082 — A Clinical Trial of Telehealth Treatment for Opioid Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07458087 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07458087.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing